EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Pre-Treatment with a Recombinant Chicken Interleukin-17A on Vaccine Induced Immunity against a Very Virulent Marek’s Disease Virus

Nitish Boodhoo, Ayumi Matsuyama-Kato, Sugandha Raj, Fatemeh Fazel, Myles St-Denis, Shayan Sharif

Viruses · 2023

DOI: 10.3390/v15081633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Nitish Boodhoo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada. Hauptthemen laut MEDLINE: Marek Disease, Vaccines, Herpesvirus 2, Gallid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ontario Ministry of Agriculture, Food and Rural Affairs, and Natural Sciences and Engineering Research Council of Canada (NSERC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The host response to pathogenic microbes can lead to expression of interleukin (IL)-17, which has antimicrobial and anti-viral activity. However, relatively little is known about the basic biological role of chicken IL-17A against avian viruses, particularly against Marek’s disease virus (MDV). We demonstrate that, following MDV infection, upregulation of IL-17A mRNA and an increase in the frequency of IL-17A+ T cells in the spleen occur compared to control chickens. To elaborate on the role of chIL-17A in MD, the full-length chIL-17A coding sequence was cloned into a pCDNA3.1-V5/HIS TOPO plasmid. The effect of treatment with pcDNA:chIL-17A plasmid in combination with a vaccine (HVT) and very virulent(vv)MDV challenge or vvMDV infection was assessed. In combination with HVT vaccination, chickens that were inoculated with the pcDNA:chIL-17A plasmid had reduced tumor incidence compared to chickens that received the empty vector control or that were vaccinated only (66.6% in the HVT + empty vector group and 73.33% in HVT group versus 53.3% in the HVT + pcDNA:chIL-17A). Further analysis demonstrated that the chickens that received the HVT vaccine and/or plasmid expressing IL-17A had lower MDV-Meq transcripts in the spleen. In conclusion, chIL-17A can influence the immunity conferred by HVT vaccination against MDV infection in chickens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Marek DiseaseVaccinesHerpesvirus 2, GallidAnimalsChickensInterleukin-17Immunologic Factors

Stichwörter der Autor:innen

IL-17AMDVTh17 cellschickensinterferon-gamma and adaptive immunity

Substanzen

Interleukin-17VaccinesImmunologic Factors

Autor:innen und Institutionen

  • Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Förderung

  • the Ontario Ministry of Agriculture, Food and Rural Affairs, and Natural Sciences and Engineering Research Council of Canada (NSERC)

Zitieren

APA

Boodhoo, N., Matsuyama-Kato, A., Raj, S., Fazel, F., St-Denis, M., & Sharif, S. (2023). Effect of Pre-Treatment with a Recombinant Chicken Interleukin-17A on Vaccine Induced Immunity against a Very Virulent Marek’s Disease Virus. Viruses. https://doi.org/10.3390/v15081633

Vancouver

Boodhoo N, Matsuyama-Kato A, Raj S, Fazel F, St-Denis M, Sharif S. Effect of Pre-Treatment with a Recombinant Chicken Interleukin-17A on Vaccine Induced Immunity against a Very Virulent Marek’s Disease Virus. Viruses. 2023. doi:10.3390/v15081633

BibTeX
@article{Boodhoo2023,
  author = {Boodhoo, Nitish and Matsuyama-Kato, Ayumi and Raj, Sugandha and Fazel, Fatemeh and St-Denis, Myles and Sharif, Shayan},
  title = {Effect of Pre-Treatment with a Recombinant Chicken Interleukin-17A on Vaccine Induced Immunity against a Very Virulent Marek’s Disease Virus},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15081633}
}
Kostenlos starten →